Cassava Sciences Swings to $78.4M Loss Amid R&D Cuts

TL;DR

**FLNA is burning cash and cutting R&D, signaling a tough road ahead for investors hoping for a quick turnaround.**

AI Summary

Cassava Sciences Inc. (FLNA) reported a significant net loss of $78.434 million for the nine months ended September 30, 2025, a substantial decline from a net income of $3.255 million in the same period of 2024. This shift was primarily driven by the absence of a $108.183 million gain from the change in fair value of warrant liabilities recognized in 2024. Total operating expenses decreased to $81.838 million for the nine months ended September 30, 2025, down from $111.959 million in 2024, largely due to a reduction in research and development expenses from $49.107 million to $22.737 million. General and administrative expenses also saw a slight decrease from $62.852 million to $59.101 million. The company's cash and cash equivalents declined to $106.080 million as of September 30, 2025, from $128.574 million at December 31, 2024, reflecting net cash used in operating activities of $22.504 million. The accumulated deficit grew to $483.545 million, indicating continued investment in drug development without product revenue. The company maintains that its current working capital will be sufficient for at least the next 12 months, despite ongoing losses and significant future cash requirements for product development.

Why It Matters

This filing reveals Cassava Sciences' continued struggle to achieve profitability, swinging from a net income to a significant net loss, which directly impacts investor confidence and valuation. The substantial reduction in R&D spending, while decreasing operating expenses, could signal a slowdown in their drug development pipeline, potentially affecting future product launches and competitive positioning in the nervous system disorder market. For employees, sustained losses and cash burn could raise concerns about job security and long-term company viability. Customers, particularly those awaiting new treatments for nervous system disorders, might see delays in product availability if R&D efforts are curtailed. The broader market will watch how FLNA manages its cash and development pipeline, especially given the competitive landscape in biopharmaceuticals.

Risk Assessment

Risk Level: high — The company reported a net loss of $78.434 million for the nine months ended September 30, 2025, and an accumulated deficit of $483.545 million, indicating a history of significant losses and no product revenue. Cash and cash equivalents decreased by $22.494 million during the nine months ended September 30, 2025, to $106.080 million, highlighting ongoing cash burn from operations.

Analyst Insight

Investors should exercise extreme caution and consider the high-risk nature of FLNA. Given the significant net losses, accumulated deficit, and reliance on future financing, potential investors should thoroughly evaluate the company's long-term viability and the progress of its drug candidates before making any investment decisions.

Financial Highlights

debt To Equity

0.59

revenue

$0

operating Margin

N/A

total Assets

$129.73M

total Debt

$48.17M

net Income

($78.4M)

eps

($1.62)

gross Margin

N/A

cash Position

$106.08M

revenue Growth

N/A

Key Numbers

• $78.4M — Net Loss (Increased from a $3.255M net income in the prior year period.)
• $106.08M — Cash and Cash Equivalents (Decreased from $128.574M at December 31, 2024.)
• $483.5M — Accumulated Deficit (Increased from $405.111M at December 31, 2024, reflecting ongoing losses.)
• $22.7M — Research and Development Expenses (Decreased significantly from $49.107M in the prior year period.)
• $22.5M — Net Cash Used in Operating Activities (Reduced from $55.664M in the prior year period, but still a significant outflow.)
• 48,307,896 — Shares Outstanding (As of November 10, 2025, showing minimal change from September 30, 2025.)
• $0.22 — Net Loss Per Share (Diluted) (For the three months ended September 30, 2025, compared to $0.58 in 2024.)
• $1.62 — Net Loss Per Share (Diluted) (For the nine months ended September 30, 2025, compared to $0.88 in 2024.)

Key Players & Entities

• Cassava Sciences, Inc. (company) — registrant
• SEC (regulator) — filing oversight
• Nasdaq Capital Market (market) — exchange for common stock
• $78.434 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $3.255 million (dollar_amount) — net income for nine months ended September 30, 2024
• $106.080 million (dollar_amount) — cash and cash equivalents at September 30, 2025
• $128.574 million (dollar_amount) — cash and cash equivalents at December 31, 2024
• $483.545 million (dollar_amount) — accumulated deficit at September 30, 2025
• $22.737 million (dollar_amount) — research and development expenses for nine months ended September 30, 2025
• $59.101 million (dollar_amount) — general and administrative expenses for nine months ended September 30, 2025

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $78.434 million for the nine months ended September 30, 2025, a significant increase from the prior year's net income of $3.255 million. This has led to an accumulated deficit of $483.545 million as of September 30, 2025. The company's ability to continue as a going concern is dependent on its ability to secure additional funding and achieve profitability.
• Decreasing Cash Reserves [high — financial]: Cash and cash equivalents decreased to $106.080 million as of September 30, 2025, from $128.574 million at December 31, 2024. This decline is attributed to net cash used in operating activities of $22.504 million for the nine months ended September 30, 2025. While the company states current working capital is sufficient for at least 12 months, significant future cash requirements for product development pose a risk.
• High Research and Development Expenses [medium — operational]: Although R&D expenses decreased to $22.737 million for the nine months ended September 30, 2025, from $49.107 million in the prior year, they remain a substantial cost. Continued investment in drug development is critical but also a significant drain on resources, especially without product revenue.
• Dependence on Drug Development Success [high — regulatory]: The company's future success is heavily reliant on the successful development and regulatory approval of its drug candidates. Any setbacks in clinical trials or regulatory processes could have a material adverse effect on the company's financial condition and prospects.
• Absence of Prior Year Fair Value Gains [medium — financial]: The significant net loss in the current period is largely due to the absence of a $108.183 million gain from the change in fair value of warrant liabilities recognized in the prior year. This highlights the volatility and non-operational nature of such gains impacting reported net income.

Industry Context

Cassava Sciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of treatments for neurodegenerative diseases. The industry is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory hurdles. Success is heavily dependent on scientific innovation, securing substantial funding, and navigating complex FDA approval processes.

Regulatory Implications

The company's primary regulatory risk lies in the lengthy and uncertain process of drug development and approval by agencies like the FDA. Any delays, adverse findings in clinical trials, or failure to meet regulatory standards for its lead drug candidates could severely impact its future prospects and financial viability.

What Investors Should Do

1. Monitor R&D spending closely: While reduced, R&D remains a significant expense. Investors should track the progress and milestones of key drug candidates to assess the justification for this spending.
2. Evaluate cash burn rate and runway: With cash reserves declining and significant future funding needs, investors must assess the company's ability to secure additional capital and its operational runway.
3. Scrutinize clinical trial data and regulatory updates: The success or failure of clinical trials and subsequent regulatory decisions are paramount. Investors should pay close attention to all published data and FDA communications.
4. Consider the impact of non-operational gains/losses: The prior year's significant gain from warrant liabilities highlights the importance of distinguishing between operational performance and one-time financial events when evaluating the company's true financial health.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates the company has historically spent more than it has earned, a common trait for development-stage biotechnology firms.)

Fair value of warrant liabilities

The estimated market price of outstanding warrants, which are financial instruments giving the holder the right to purchase company stock at a specific price. Changes in this value can significantly impact net income. (A large gain from this in the prior year masked operational losses, making the current year's net loss appear more severe by comparison.)

Net cash used in operating activities

The amount of cash a company has spent on its core business operations over a period. A negative number indicates cash outflows exceed inflows from operations. (Shows the company is burning cash to fund its ongoing operations and development efforts.)

Diluted net loss per share

The net loss per share after accounting for all potential dilutive securities, such as stock options and warrants, that could increase the number of outstanding shares. (Provides a more conservative view of the company's per-share performance, reflecting the potential impact of future share issuances.)

Year-Over-Year Comparison

Compared to the prior year period, Cassava Sciences has shifted from a net income of $3.255 million to a net loss of $78.434 million for the nine months ended September 30, 2025. This dramatic change is primarily due to the absence of a $108.183 million gain from warrant liabilities recognized in 2024. Total operating expenses have decreased due to lower R&D spending, but cash reserves have also declined, and the accumulated deficit has grown, underscoring the ongoing challenges of drug development without product revenue.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SAVA Nasdaq Capital Marke

Filing Documents

• sava20250930_10q.htm (10-Q) — 1056KB
• ex_855814.htm (EX-31.1) — 13KB
• ex_855815.htm (EX-31.2) — 14KB
• ex_855816.htm (EX-32.1) — 7KB
• 0001437749-25-034427.txt ( ) — 5329KB
• sava-20250930.xsd (EX-101.SCH) — 48KB
• sava-20250930_cal.xml (EX-101.CAL) — 30KB
• sava-20250930_def.xml (EX-101.DEF) — 308KB
• sava-20250930_lab.xml (EX-101.LAB) — 281KB
• sava-20250930_pre.xml (EX-101.PRE) — 337KB
• sava20250930_10q_htm.xml (XML) — 866KB

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets – September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Changes in Stockholders' Equity - Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

Signatures

Signatures 31 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CASSAVA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, In thousands, except share and par value data) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 106,080 $ 128,574 Prepaid expenses and other current assets 2,830 7,958 Total current assets 108,910 136,532 Property and equipment, net 20,823 21,001 Total assets $ 129,733 $ 157,533 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 46,092 $ 7,654 Accrued development expense 1,366 2,440 Accrued compensation and benefits 362 1,357 Other current liabilities 226 299 Total current liabilities 48,046 11,750 Other non-current liabilities 119 79 Total liabilities 48,165 11,829 Commitments and contingencies (Notes 8, 9 and 10) Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized, none issued and outstanding — — Common stock, $ 0.001 par value; 120,000,000 shares authorized; 48,307,896 and 48,203,179 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 48 48 Additional paid-in capital 565,065 550,767 Accumulated deficit ( 483,545 ) ( 405,111 ) Total stockholders' equity 81,568 145,704 Total liabilities and stockholders' equity $ 129,733 $ 157,533 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents CASSAVA SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Three months ended Nine months ended September 30, September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 3,955 $ 17,676 $ 22,737 $ 49,107 General and administrative 7,905 12,947 59,101 62,852 Total operating expenses 11,860 30,623 81,838 111,959 Operating loss ( 11,860 ) ( 30,623 ) ( 81,838 ) ( 111,959 ) Inte

View Full Filing

View this 10-Q filing on SEC EDGAR